Is There Age Bias in the Treatment of Localized Prostate Carcinoma?

Cancer

Volumn 100, Issue 1, 2004, Pages 72-81

  Alibhai, Shabbir M H ^a,b,c,d   Krahn, Murray D ^a,c,d   Cohen, Marsha M ^d,e   Fleshner, Neil E ^c   Tomlinson, George A ^a,c,d   Naglie, Gary ^a,b,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Age; Age factors; Comorbidity; Life expectancy; Prostatectomy; Prostatic neoplasms; Radiotherap

Indexed keywords

ADULT; AGED; AGING; CANCER RADIOTHERAPY; COHORT ANALYSIS; COMORBIDITY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CARCINOMA; COHORT STUDIES; COMORBIDITY; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES;

EID: 0346217049     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11884     Document Type: Review

References (62)

1. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patient. JAMA. 1986;255:3385-3390.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA. 1997;47:5-27.
3. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269:2633-2636.
4. Severson RK, Montie JE, Porter AT, Demers RY. Recent trends in incidence and treatment of prostate cancer among elderly men. J Natl Cancer Inst. 1995;87:532-534.
5. Mettlin C. Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on cancer studies, 1974-1993. Prostate 1997;32(3): 221-226.
6. Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff RM. Patterns of care related to age of men with prostate cancer. Cancer. 1991;67:2633-2641.
7. Post PN, Kil PJM, Hendrikx AJM, Janssen-Heijnen MLG, Crommelin MA, Coebergh JWW. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int. 1999;84:652-656.
8. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000;88:1122-1130.
9. Aus G, Abbou CC, Pacik D, et al. EAU guidelines on prostate cancer. Eur Urol. 2001;40:97-101.
10. Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology. 2003;61(2 Suppl 1):14-24.
11. Menon M, Parulkar BG, Baker S. Should we treat localized prostate cancer? An opinion. Urology. 1995;46:607-616.
12. Koch MO, Miller DA, Butler R, Lebos L, Collings D, Smith JAJ. Are we selecting the right patients for treatment of localized prostate cancer? Results of an actuarial analysis. Urology. 1998;51:197-202.
13. Donovan JL, Frankel SJ, Faulkner A, Selley S, Gillatt D, Hamdy FC. Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom. BMJ. 1999;318:299-300.
14. Fowler FJ Jr., McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000;283:3217-3222.
15. Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology. 2002;60:258-263.
16. Albertsen PC, Fryback DG, Storer BE, Kolon F, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 1996;156:127-132.
17. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst. 2000;92:613-621.
18. Wetle T. Age as a risk factor for inadequate treatment. JAMA. 1987;258:516.
19. Holowaty EJ, Moravan V, Lee G, Chong N, Dale D. A reabstraction study to estimate the completeness and accuracy of data elements in the Ontario Cancer Registry. Report to Health Canada, Ottowa, Ontario, February 27, 1996.
20. Robles SC, Marrett LD, Clarke EA, Risch HA. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988;41:495-501.
21. Canadian Medical Association. Canadian Medical Directory 1999. Don Mills, Canada: Southam Information Products Group, 1999.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383.
23. Greenfield S, Aronow HU, Elashoff RM, Watanabe D. Flaws in mortality data: the hazards of ignoring comorbid disease. JAMA. 1988;260:2253-2255.
24. Melfi C, Holleman E, Arthur D, Katz B. Selecting a patient characteristics index for the prediction of medical outcomes using administrative claims data. J Clin Epidemiol. 1995;48:917-926.
25. Rochon PA, Katz JN, Morrow LA, et al. Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability. Med Care. 1996;34:1093-1101.
26. Glynn RJ, Monane M, Gurwitz JH, Choodnovskiy I, Avorn J. Aging, comorbidity, and reduced rates of drug treatment for diabetes mellitus. J Clin Epidemiol. 1999;52:781-790.
27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
28. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626-631.
29. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781-789.
30. Agresti A. An introduction to categorical data analysis. New York: John Wiley & Sons, 1996.
31. Hosmer DW, Taber S, Lemeshow S. The importance of assessing the fit of logistic regression models: a case study. Am J Public Health. 1991;81:1630-1635.
32. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
33. Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment of local and regional prostate cancer. Med Care. 1996;34:152-162.
34. Potosky AL, Merrill RM, Riley GF, et al. Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. Health Serv Res. 1999;34:525-546.
35. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001;93:1864-1871.
36. Wasson JH, Bubolz TA, Yao GL, Barry MJ. Prostate biopsies in men with limited life expectancy. Effective Clin Practice. 2002;5:137-142.
37. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998;16:275-283.
38. Lu-Yao GL, Albertsen P, Warren J, Yao S-L. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy-a population-based study. Urology. 1999;54:301-307.
39. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283:354-360.
40. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAAIA. 1998;280:975-980.
41. Fleshner N, Rakovitch E, Klotz L. Differences between urologists in the United States and Canada in the approach to prostate cancer. J Urol. 2000;163:1461-1466.
42. Savage P, Bates C, Abel P, Waxman J. British urological surgery practice: 1. Prostate cancer. Br J Urol. 1997;79:749-754; discussion 754-755.
43. Walsh PC. Survival of men with clinically localized prostate cancer detected in the eighth decade of life [Comment]. J Urol. 1994;151:1329.
44. Bremnes RM, Andersen K, Wist EA. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer. 1995;31A:1955-1959.
45. Mazur DJ, Hickam DH. Patient preferences for management of localized prostate cancer. West J Med. 1996;165:26-30.
46. Crawford ED, Bennett CL, Stone NN, et al. Comparison of perspectives on prostate cancer: analyses of survey data. Urology. 1997;50:366-372.
47. Mazur DJ, Merz JF. How older patients' treatment preferences are influenced by disclosures about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer. J Am Geriatr Soc. 1996;44:934-937.
48. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63-74.
49. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Making decisions about treatment for localized prostate cancer. BJU Int. 2002;89:255-260.
50. O'Rourke ME. Narrowing the options: the process of deciding on prostate cancer treatment. Cancer Invest. 1999;17:349-359.
51. O'Rourke ME. Decision making and prostate cancer treatment selection: a review. Semin Oncol Nurs. 2001;17:108-117.
52. Eapen L, Villeneuve PJ, Levy IG, Morrison HI. Comorbid survival among elderly male participants of the Canada health survey: relevance to prostate cancer screening and treatment. Chron Dis Can. 1998;19:84-90.
53. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults. JAMA. 1998;279:585-592.
54. Minino AM, Smith BL. Deaths: preliminary data for 2000. Natl Vital Stat Rep. 2001;49:1-40.
55. Kupelian PA, Buchsbaum JC, Patel C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 2002;52:704-711.
56. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48:629-633.
57. Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol. 2002;168:525-529.
58. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol. 1995;154:2144-2148.
59. Inouye SK, Peduzzi PN, Robison JT, Hughes JS, Horwitz RI, Concato J. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA. 1998;279:1187-1193.
60. Moore MJ, O'Sullivan B, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol. 1988;6:1736-1745.
61. Bubolz T, Wasson JH, Lu-Yao G, Barry MJ. Treatments for prostate cancer in older men: 1984-1997. Urology. 2001;58:977-982.
62. Moul JW, Wu H, Sun L, et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 2002;132:213-219.